Skip to main content

Advertisement

Springer Nature Link
Log in

Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Current medication for gastric cancer patients has a low success rate and the patients develop rapid tolerance to these drugs. Therefore, the development of new regimens is desired. In this study, we determined that Notch-signaling-related genes were overexpressed and activated in gastric cancer patients and gastric cancer cell lines. According to recent studies, γ-secretase inhibitors (GSIs), which function as Notch signaling inhibitors, could be used as therapeutic drugs in cancer. We demonstrated that GSI I (cbz-IL-CHO) is the most effective GSI in gastric cancer cells. We also determined the cell survival signaling-related proteins that were affected by GSI I. The levels of phosphorylated AKT were significantly decreased upon GSI I treatment, and constitutively activated myristoylated AKT completely blocked GSI I-induced apoptosis and cell survival, suggesting that inhibition of AKT signaling is critical for GSI I-mediated effects in gastric cancer cells. In order to maximize the effects and safety of GSI I, a combination treatment with GSI I and 5-FU was performed. Inhibition of gastric cancer cell proliferation with the combination treatment was significantly better than that with the single treatment. All phosphorylated forms of AKT, p44/42, JNK, and p38 were drastically changed by the combination treatment. Orthotopically transplanted gastric tumor burdens in mice were reduced using the combined treatment. The outcomes of this study clearly demonstrated the therapeutic potential of GSI I in gastric cancer, as well as the greater efficacy of the combined treatment of GSI I with 5-FU. Therefore, we suggest that further clinical trials examining the potential of combined GSI I and 5-FU treatment in gastric cancer patients be undertaken.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

GSI:

γ-Secretase inhibitor

AGC:

Advanced gastric cancer

T-ALL:

T cell acute lymphoblastic leukemia

NICD1:

Notch-1 intracellular domain

NICD2:

Notch-2 intracellular domain

Myr-AKT:

Myristoylated AKT (constitutively active form of AKT)

LRP:

Low-density lipoprotein receptor-related protein

EMT:

Epithelial-mesenchymal transition

References

  1. De Vita F et al (2012) Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets 16(Suppl 2):S29–S34

    Article  PubMed  Google Scholar 

  2. Satoh T, Sakata Y (2012) S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 13(13):1943–1959

    Article  CAS  PubMed  Google Scholar 

  3. Ajani JA et al (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 study group. J Clin Oncol 25(22):3205

    Article  CAS  PubMed  Google Scholar 

  4. Dreesen O, Brivanlou AH (2007) Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 3(1):7–17

    Article  CAS  PubMed  Google Scholar 

  5. Knowlton AA (2006) NFkappaB, heat shock proteins, HSF-1, and inflammation. Cardiovasc Res 69(1):7–8

    Article  CAS  PubMed  Google Scholar 

  6. Mivechi NF et al (1994) Analysis of HSF-1 phosphorylation in A549 cells treated with a variety of stresses. Int J Hyperth 10(3):371–379

    Article  CAS  Google Scholar 

  7. Dickson BC et al (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20(6):685–693

    Article  CAS  PubMed  Google Scholar 

  8. Park JT et al (2006) Notch3 gene amplification in ovarian cancer. Cancer Res 66(12):6312–6318

    Article  CAS  PubMed  Google Scholar 

  9. O’Neil J et al (2006) Activating notch1 mutations in mouse models of T-ALL. Blood 107(2):781–785

    Article  PubMed Central  PubMed  Google Scholar 

  10. Shih I-M, Wang T-L (2007) Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res 67(5):1879–1882

    Article  CAS  PubMed  Google Scholar 

  11. Curry CL et al (2005) Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi’s sarcoma tumor cells. Oncogene 24(42):6333–6344

    CAS  PubMed  Google Scholar 

  12. Zhang Y et al (2001) Heat shock factor-4 (HSF-4a) is a repressor of HSF-1 mediated transcription. J Cell Biochem 82(4):692–703

    Article  CAS  PubMed  Google Scholar 

  13. Wong GTMD, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876–12882

    Article  CAS  PubMed  Google Scholar 

  14. Vaisman N, Evgen’ev MB, Golubovskii MD (2012) [Parallelism and paradoxes on viability and the life span of two loss-of-function mutations: heat shock protein transcriptional regulator hsf (1) and l (2) gl tumor suppressor in D. melanogaster]. Izvestiia Akademii Nauk Seriia biologicheskaia/Rossiiskaia Akademiia Nauk 1:27–34

    PubMed  Google Scholar 

  15. Kim SJ et al (2014) Up-regulation of neogenin-1 increases cell proliferation and motility in gastric cancer. Oncotarget 5(10):3386–3398

    PubMed Central  PubMed  Google Scholar 

  16. Kim SJ et al (2012) MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res 14(1):R14

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Kim SJ et al (2013) Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 4(9):1461

    PubMed Central  PubMed  Google Scholar 

  18. Lee HW, Jang KS, Chun KH (2014) Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy. BMB Rep 47(12):697

    Article  PubMed Central  PubMed  Google Scholar 

  19. Cheong TC, Shin JY, Chun KH (2010) Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci 101(1):94–102

    Article  CAS  PubMed  Google Scholar 

  20. Choi SW et al (2015) Glucose deprivation triggers protein kinase C-dependent beta-catenin proteasomal degradation. J Biol Chem 290(15):9863–9873

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Ahn YH et al (2012) STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy. Clin Exp Metastasis 29(4):359–369

    Article  CAS  PubMed  Google Scholar 

  22. Kim SJ et al (2014) Ablation of galectin-3 induces p27(KIP1)-dependent premature senescence without oncogenic stress. Cell Death Differ 21(11):1769–1779

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Wang YG et al (2012) Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp Mol Med 44(6):387–393

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Cho Y et al (2015) Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget 6(11):8709–8721

    PubMed Central  PubMed  Google Scholar 

  25. Baek JH et al (2014) Galectin-3 activates PPARgamma and supports white adipose tissue formation and high-fat diet-induced obesity. Endocrinology 156(1):147–156

    Article  Google Scholar 

  26. Kim SJ et al (2011) Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 155(3):427–434

    Article  CAS  PubMed  Google Scholar 

  27. Ko A et al (2012) Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF. J Natl Cancer Inst 104(21):1660–1672

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Palomero T, Dominguez M, Ferrando AA (2008) The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 7(8):965–970

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Palomero T, Ferrando A (2008) Oncogenic NOTCH1 control of MYC and PI3 K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res 14(17):5314–5317

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Yeh TS et al (2009) The activated notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res 69(12):5039–5048

    Article  CAS  PubMed  Google Scholar 

  31. Miele L (2006) Notch signaling. Clin Cancer Res 12(4):1074–1079

    Article  CAS  PubMed  Google Scholar 

  32. Reedijk MOS, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 15:8530–8537

    Article  Google Scholar 

  33. Santagata S et al (2004) JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 64(19):6854–6857

    Article  CAS  PubMed  Google Scholar 

  34. Kim SJ et al (2015) Activation of nuclear PTEN by inhibition of notch signaling induces G2/M cell cycle arrest in gastric cancer. Oncogene. doi:10.1038/onc.2015.80

    Google Scholar 

  35. Mulligan P et al (2011) A SIRT1-LSD1 corepressor complex regulates notch target gene expression and development. Mol Cell 42(5):689–699

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. King IN et al (2006) Hrt and Hes negatively regulate Notch signaling through interactions with RBP-Jkappa. Biochem Biophys Res Commun 345(1):446–452

    Article  CAS  PubMed  Google Scholar 

  37. Ou-Yang HF et al (2009) Notch signaling regulates the FOXP3 promoter through RBP-J- and Hes1-dependent mechanisms. Mol Cell Biochem 320(1–2):109–114

    Article  CAS  PubMed  Google Scholar 

  38. Fortini ME (2002) [gamma]-Secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol 3(9):673–684

    Article  CAS  PubMed  Google Scholar 

  39. Langlois B et al (2010) LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 5(7):e11584

    Article  PubMed Central  PubMed  Google Scholar 

  40. Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46(7):1271–1277

    Article  CAS  PubMed  Google Scholar 

  41. Cecilia Sahlgren MVG, Jin S, Poellinger L, Lendahl U (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci 105:6392–6397

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Ryoichiro Kegeyama for kindly providing the pHES1-luc reporter gene construct. This project was supported by a Grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI11C0926 and A121982), the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. NRF-2014R1A2A1A11050600), and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. NRF-2010-0022436).

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea

    Hyun-Woo Lee, Seok-Jun Kim & Kyung-Hee Chun

  2. Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea

    Hyun-Woo Lee & Jaewhan Song

  3. Center for Gastric Cancer, National Cancer Center, Goyang, Republic of Korea

    Il Ju Choi

  4. Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea

    Seok-Jun Kim & Kyung-Hee Chun

Authors
  1. Hyun-Woo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seok-Jun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Il Ju Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jaewhan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyung-Hee Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyung-Hee Chun.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict interests.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 325 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, HW., Kim, SJ., Choi, I.J. et al. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer. Clin Exp Metastasis 32, 593–603 (2015). https://doi.org/10.1007/s10585-015-9730-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-015-9730-5

Keywords

Search

Navigation